AgBiome
AgBiome is a biotechnology company that develops crop protection products. Its proprietary GENESIS™ platform led to its flagship fungicide, Howler®.
Secondary Market Price
How AgBiome Measures Up
To help you manage your AgBiome equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series D
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of AgBiome's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future AgBiome Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for AgBiome's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
AgBiome is a biotechnology research company that discovers and develops biological and trait products for crop protection. The company utilizes its proprietary GENESIS™ discovery platform to capture and screen microbes for controlling insects, diseases, and nematodes. Through its commercial subsidiary, AgBiome develops and sells its own crop protection solutions, the first of which was a fungicide named Howler®. Founded in 2012 by John Ryals and Jeff Dangl, the company is headquartered in Research Triangle Park, North Carolina, and serves sectors that include crop protection, food, and human and animal health.
While AgBiome has not publicly outlined specific future product roadmaps, its activities suggest a continued focus on discovering and commercializing new biological products. A notable recent development for the company was a Series D funding round that closed on October 14, 2021, raising $116 million. Key investors in this round included Blue Horizon Corporation and Novalis LifeSciences.
- Blue Horizon
- Novalis LifeSciences
- Polaris Partners
- ARCH Venture Partners
- Fidelity Investments Inc.
- UTIMCO
- Pontifax AgTech
- Innotech Advisors
- Syngenta Ventures
- Leaps by Bayer
- Novozymes
- Bill & Melinda Gates Foundation
- Monsanto Growth Ventures
- Co-Founder, Scott Uknes
- Co-Founder, Eric Ward
- Co-Founder, Jeff Dangl
- Co-Founder, Paul Schulze-Lefert
- Co-Founder, John Ryals
- Co-Founder, Mike Koziel
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is AgBiome worth joining?
Deciding whether to join AgBiome depends on your personal career goals and financial situation. Tools like Prospect can help you model the potential value of your equity compensation, which is a critical factor in your decision.
What should I do with my AgBiome stock?
Managing private stock involves complex decisions around when to exercise options and how to minimize taxes. Using a platform like Prospect can help you create a personalized strategy to maximize the post-tax value of your AgBiome equity.
Can you sell AgBiome stock?
As a private company, selling AgBiome stock is typically possible only during specific events like tender offers or on secondary markets. Prospect offers tender offer tools to help you decide how much to sell and identify the most tax-optimal shares.
How can I find the value of my AgBiome stock?
The value of private stock like AgBiome's isn't publicly listed and is determined by internal 409A valuations and funding rounds. Platforms such as Prospect use predictive models trained on venture capital data to help you forecast the future value of your shares.
What is AgBiome's equity worth?
The precise worth of AgBiome's equity is not public information, as it is a private company. You can estimate its potential future value using specialized tools like Prospect, which analyzes your holdings to model different financial scenarios.
What is AgBiome's stock ticker symbol?
AgBiome does not have a stock ticker symbol because it is a private company and its shares are not traded on a public stock exchange. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO).
Can I buy or sell AgBiome stock?
As AgBiome is a private company, its stock is not available for purchase on public markets, and buying opportunities are typically limited to accredited investors in private funding rounds. Selling is generally restricted to company-approved tender offers or secondary market transactions, which platforms like Prospect can help you navigate.
What is the criteria to buy or invest in AgBiome stock?
Investing in a private company like AgBiome is typically restricted to accredited investors who participate in private financing rounds. Employees may also receive equity in the form of stock options or RSUs as part of their compensation package.
